After 16 Years, Federal Parity Rules Finally Force Insurers to Cover Addiction

Two things: first, an editorial layer. Most treatment directories publish 300-word boilerplate beside facility listings; Pacific Shores is run like a small news desk, with longer-form reporting on the policy, research, and economics of addiction care. Second, transparent sourcing — every factual claim in a guide ties back to a named primary source (SAMHSA TIP, NIDA Research Report, peer-reviewed trial, CMS sub-regulatory guidance). Our goal is to be the publication a clinician would forward to a patient, not the one a patient forwards to no one.

The editorial team is a small in-house group led by a staff editor with ten years of substance-use policy writing experience. Drafts go through a five-stage review — draft → source verification → clinical alignment against ASAM / SAMHSA / DSM-5-TR → transparent attribution → periodic refresh. Where a piece requires licensed clinical input (medication safety, detoxification protocols) we commission a review from a board-certified addiction physician and name them on the page.

When a reader calls our helpline and ultimately enters treatment at an in-network partner facility, we may earn a placement fee from that facility. That is the standard economic model for treatment-information publishing; we disclose it rather than hide it. The SAMHSA public helpline (1-800-662-HELP) is free, and we publish it alongside our own on every relevant page so readers always have a free alternative.

Yes. Our clinical line — which we inherited from the NIDA / SAMHSA / ASAM consensus, not from any industry source — is that for opioid use disorder, medication-assisted treatment (buprenorphine, methadone, naltrexone) is the standard of care. Cumulative Cochrane evidence across 60+ RCTs shows MAT cuts overdose mortality roughly in half. Programs that refuse MAT are working outside the current evidence base, and we say so on every page where the topic comes up.

We track its implementation closely because it is the biggest regulatory shift in addiction benefits in over a decade. Our editorial position: the rule's theoretical protections only translate into real access when members know how to invoke them. To that end, our insurer pages include specific, actionable language for parity-based appeals, and our newsletter covers enforcement actions as they are reported. We think the gap between what the rule requires and what plans currently deliver is the most important under-reported story in addiction coverage.

The site is journalism — reporting, explaining, contextualising — not personalised medical advice. A medical-advice site would need to know the specific clinical presentation of each reader, which is the job of a licensed clinician with a chart in front of them, not a website. We design the coverage to make readers smarter about the decisions they face, without substituting for the clinical conversation they need to have with someone who can evaluate their case.

Regulatory and insurance content is reviewed at least once a year; where the underlying rule changes (as in September 2024 and January 2025 for parity), affected pages are updated within four weeks. Research-dependent content is updated when NIDA, SAMHSA, or peer-reviewed literature shifts the consensus. Every page displays its last-reviewed date at the top; corrections are logged visibly, not silently overwritten.

Short excerpts with attribution, yes. Full republication requires permission; write to [email protected]. We are particularly open to arrangements with clinical training programs, county behavioural health authorities, and non-commercial publishers. Commercial republication by treatment providers or lead generators is not permitted.